MONTREAL, May 2nd, 2022 – Replicor Inc., announced the participation of its CSO, Dr. Andrew Vaillant, at
the 2nd Annual CHB Drug Development Congress, held April 25 – 27th, 2022 in Boston, MA, USA (click here).
Dr. Vaillant presented updates in the field on the following important topics:
- Understanding of the relative impact and mechanisms of action of agents in development to
target HBV subviral particles (HBsAg) click here.
- Lessons learned regarding the impact of current agents in development to target cccDNA and
challenges in achieving sterilizing cure click here.
- The critical importance of both clearing subviral particles and the development of transaminase
flares during therapy in achieving functional cure click here.
Dr. Vaillant commented, “our evolving understanding of how different agents in development are working in clinical trials will continue to inform the field on the potential of various combination therapies to achieve functional cure of HBV”.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com